Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Rubinchik

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Gene Therapy|September 26, 2001
Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cellsS L Lowe, S Rubinchik, T Honda, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 16, 2001
A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expressionS Rubinchik, D Wang, H Yu, et al.
Clinical and Experimental Rheumatology|September 4, 2004
The 72-kilodalton IE-1 protein of human cytomegalovirus (HCMV) is a potent inducer of connective tissue growth factor (CTGF) in human dermal fibroblastsM Markiewicz, E A Smith, S Rubinchik, et al.
Current Gene Therapy|July 12, 2002
The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancerJ S Norris, M L Hyer, C Voelkel-Johnson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 5, 2006
Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancerXiang Liu, S Elojeimy, A M El-Zawahry, et al.
Cancer Gene Therapy|June 10, 2006
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status reportJ S Norris, A Bielawska, T Day, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Gene Therapy|September 26, 2001
Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cellsS L Lowe, S Rubinchik, T Honda, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 16, 2001
A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expressionS Rubinchik, D Wang, H Yu, et al.
Clinical and Experimental Rheumatology|September 4, 2004
The 72-kilodalton IE-1 protein of human cytomegalovirus (HCMV) is a potent inducer of connective tissue growth factor (CTGF) in human dermal fibroblastsM Markiewicz, E A Smith, S Rubinchik, et al.
Current Gene Therapy|July 12, 2002
The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancerJ S Norris, M L Hyer, C Voelkel-Johnson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 5, 2006
Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancerXiang Liu, S Elojeimy, A M El-Zawahry, et al.
Cancer Gene Therapy|June 10, 2006
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status reportJ S Norris, A Bielawska, T Day, et al.
Pageof 2